Assessment of Serum Survivin Levels as a Potential Biomarker for Disease Severity and Therapeutic Outcome: Results of a Pilot Study Authors: Kuruva Janakiramudu, Sumita Halder, Rajarshi Kar, Chander Grover, Rachna Gupta, Edelburt A. Almeida Published: 2026 ABSTRACT Background:Psoriasis is a chronic inflammatory skin disease characterized by hyperproliferation of keratinocytes and immune dysregulation. Survivin, being an apoptosis inhibitor, could be a potential biomarker for psoriasis.Aim and Objectives:To evaluate serum survivin levels in moderate to severe psoriasis patients before and after methotrexate therapy and to assess its correlation with disease severity using Psoriasis Area and Severity Index (PASI).Patients and Methods:This study included 30 patients with moderate to severe psoriasis and 30 healthy controls. Serum survivin levels were measured at baseline and at 12 weeks of methotrexate therapy. Disease severity was assessed using PASI.Results:Serum survivin levels were considerably higher in psoriasis patients than in controls (70.3 ± 16.9 vs. 22.1 ± 9.4 pg/mL; P < 0.001). Following methotrexate therapy, serum survivin levels decreased (20.9 ± 8.0 pg/mL; P < 0.001) and PASI scores reduced in tandem from 15.3 ± 4.8 to 7.5 ± 4.4 (P < 0.001). Improvement in PASI was significantly associated with survivin reduction (r = 0.672; P < 0.001).Limitations:Small sample size, short follow-up duration, and lack of histopathological assessment or tissue survivin evaluation. Additionally, the absence of long-term follow-up and potential noncompliance with smoking/alcohol abstinence may have influenced the findings.Conclusion:Serum survivin levels were significantly elevated in psoriasis patients compared to healthy controls and were reduced significantly following treatment with methotrexate. These changes in serum survivin levels corresponded well with decreasing PASI scores in psoriasis patients, suggesting survivin as a potential biomarker of disease activity and therapeutic response. Introduction Psoriasis is a chronic, immune-mediated inflammatory skin disorder affecting approximately 2–3% of the global population, with higher prevalence in Western countries compared to East Asian and Sub-Saharan African populations.[12] The disease is characterized by epidermal hyperproliferation, aberrant keratinocyte differentiation, and persistent inflammation predominantly driven by the IL-23/IL-17 axis and Th1/Th17- mediated immune responses.[3] Among the various subtypes, chronic plaque psoriasis (psoriasis vulgaris), characterized clinically by well-demarcated, erythematous, indurated plaques with silvery scales involving the scalp, elbows, knees, and lower back, accounts for 80–90% of the cases.[45] However, psoriasis is not merely a cutaneous disease; it is associated with several comorbidities and has profound psychological and social ramifications for the affected individual. The pathogenesis of psoriasis involves a complex interaction of genetic susceptibility, environmental triggers, and immune dysregulation.[67] Several biomarkers have been investigated for their role in disease activity, progression, and response to therapies. Recently, survivin has emerged as a promising candidate due to its pivotal role in inhibiting apoptosis and promoting cell proliferation. Survivin, a 16.5 kDa protein encoded by the BIRC5 (baculoviral inhibitor of apoptosis repeat-containing 5) gene, belongs to the inhibitor of apoptosis protein (IAP) family.[8] It is normally expressed during embryonic development but is largely absent in terminally differentiated adult tissues. Survivin is re-expressed in several pathological conditions, including cancers, autoimmune diseases, and chronic inflammatory disorders such as psoriasis. It functions by inhibiting caspase activation and stabilizing microtubules during mitosis and facilitates unchecked cellular proliferation and survival.[9] Increased survivin expression detected in epidermal keratinocytes, inflammatory cells, and serum of patients with psoriasis suggests its role in keratinocyte hyperplasia and apoptosis resistance, which are the hallmark features of psoriatic skin lesions.[10] Elevated serum survivin levels correlating positively with disease severity reported in recent studies indicate its potential utility as a noninvasive biomarker for monitoring disease activity and therapeutic outcomes.[11] We studied serum survivin levels in patients with moderate to severe psoriasis and age-matched healthy controls and correlated these levels with the Psoriasis Area and Severity Index (PASI) before and after methotrexate therapy. The objective of the study was to investigate if survivin could be a reliable biomarker for clinical disease severity and therapeutic outcome. Patients and Methods Sample size was calculated using survivin variance reported by Akpınar et al.[11] (standard deviation [SD] ≈ 44.7 pg/mL) and a paired pre-post design (α = 0.05, power = 80%). A sample size of ~26 patients was considered adequate to detect a mean reduction in serum survivin levels of 25 pg/mL. Considering a 10% dropout rate, 30 adult patients aged 18 to 60 years having moderate to severe chronic plaque psoriasis (PASI >10) for at least 12 months were included. Thirty age- and sex-matched healthy controls were enrolled. The participants were enrolled after obtaining informed written consent, ensuring participant autonomy, confidentiality, and data protection throughout the study. This prospective 12-week study was conducted between June 2023 and June 2024 after approval by the Institutional Ethics Committee-Human Research (Approval number: IECHR202359150, date of approval: 30/04/2023). Pregnant and lactating women and individuals with pre-existing liver disease, anemia, malignancy, neurological or autoimmune disorders, or conditions known to influence serum survivin levels were excluded. Patients were asked to stop therapy for 2 months, or 1 month prior to the first blood sampling if they were taking oral medications, or applying topical medications, respectively. Only topical emollients and oral antihistamines were allowed before baseline sampling. The demographic profile, duration and evolution of psoriasis, detailed medical history, and personal and family history were recorded. The clinical severity of psoriasis was graded according to PASI scores as mild (PASI < 10) or moderate to severe (PASI > 10) at baseline, 4, 8, and 12 weeks of methotrexate treatment.[12] Individual (1:1) matching was performed between cases and controls across all categories. Laboratory assessment A total of 5 mL blood sample was collected from each patient and control after overnight fasting between 10:00 PM to 6:00 AM by antecubital venipuncture. The serum was separated and stored at -200 C until analysis. Additionally, complete blood counts, fasting plasma glucose, lipid profile (by autoanalyzer), liver and renal function tests were performed. Other investigations were performed as deemed necessary for the management. Serum survivin levels were estimated in the institutional biochemical research laboratory. Serum survivin levels were measured quantitatively by the standard ELISA method at baseline and then at every 4 week interval during methotrexate treatment and at the end of the study period. ELISA was done as per the manufacturer’s protocol by using a human survivin ELISA kit (from ELK Biotechnology Company ready-to-use in vitro kits). Treatment protocol All patients were administered oral methotrexate at a dose of 0.12–0.2 mg/kg/week (maximum dose not exceeding 10 mg/week) for 12 weeks. Monitoring for treatment adherence, adverse effects, PASI scores, laboratory parameters, and serum survivin levels was performed at 4-week intervals. Statistical analysis SPSS v26.0 was used for the data analyses. Shapiro–Wilk test was used to evaluate data normality; variables were reported as mean ± standard deviation (SD) or median (interquartile range [IQR]). In cases where serum survivin levels at baseline and after 12 weeks were not normally distributed, nonparametric tests of significance were used for comparison. The Wilcoxon signed-rank test examined changes before and after therapy, while the Mann–Whitney U test was used to compare survivin levels between groups. Tukey’s post-hoc analysis was used to examine the PASI scores using repeated-measures ANOVA. For the relationship between survivin and PASI scores, multiple linear regression was used to identify survivin’s predictors. Results Table 1 depicts baseline characteristics and serum survivin profiles of patients and controls. The 30 patients comprised 17 males and 13 females (M:F = 1.31:1) aged between 18 and 59 years (mean + SD = 36.8 ± 13.5 years). A majority, 12 (40%) patients, were ≤30 years of age. Table 1Baseline characteristics of psoriasis patients and controlsBaseline characteristicsParametersPatients n=30 (%)Controls n=30 (%) P GenderMales (M)17 (56.7)17 (56.7)-Females (F)13 (43.3)13 (43.3)-M:F1.311.31-Age in yearsRange18-5918-59Mean±SD36.8±13.536±12.1≤2000-21-3012 (40)12 (40)-31-406 (20.0)6 (20.0)-41-506 (20.0)6 (20.0)-51-606 (20.0)6 (20.0)-Duration of psoriasis in yearsRange1-20 years--<55 (16.7)--5-1016 (53.3)-->109 (30)--PASI score (severity)>10 (moderate to severe)30--At baselineMean±SD15.32±4.8-<0.001** (for cases: baseline vs 12 weeks)At 12 weeks of treatmentMean±SD7.48±4.4-Serum survivin levels in pg/mL at baselineRange47.0−113.69.8−41.9<0.001* (comparison between cases and controls at baseline)Mean±SD70.3±16.922.1±9.4Median (IQR)68.5 (55.5−78.1)20.5 (13.8−28.6),Serum survivin levels in pg/mL at 12 weeks of treatmentRange10.9−28.9-<0.001** (comparison between cases at baseline and 12 weeks)Mean±SD20.9±8.0-IQR, interquartile range; PASI, psoriasis area severity index; SD, Standard Deviation. *Mann–Whitney U test, ** Wilcoxon signed rank test, P<0.05 calculated at 5% level (95% confidence limit) was considered significant. Statistical comparison for matched variables (age and sex) is not applicable Baseline characteristics of psoriasis patients and controls IQR, interquartile range; PASI, psoriasis area severity index; SD, Standard Deviation. *Mann–Whitney U test, ** Wilcoxon signed rank test, P<0.05 calculated at 5% level (95% confidence limit) was considered significant. Statistical comparison for matched variables (age and sex) is not applicable Serum survivin levels: Baseline comparison between patients and controls The baseline serum survivin values in patients varied between 47.0 and 113.6 pg/mL (mean ± SD, 70.3 ± 16.9 pg/mL), and the median (IQR) value was 68.5 (55.5–78.1) pg/mL. The baseline serum survivin values in controls varied between 9.8 and 41.9 pg/mL (mean ± SD, 22.1 ± 9.4 pg/mL), and the median (IQR) value was 20.5 (13.8–28.6) pg/mL. The survivin levels were significantly higher in psoriasis patients compared to healthy controls (P < 0.001). PASI score and serum survivin levels in patients after treatment with methotrexate With methotrexate treatment, there was a consistent and statistically significant decrease in mean (± SD) PASI score from baseline values of 15.3 ± 4.8 to 13.2 ± 4.7 at 4 weeks, 10.7 ± 4.4 at 8 weeks, and 7.5 ± 4.4 at 12 weeks (P < 0.001) [Figure 1]. Correspondingly, serum mean (± SD) survivin levels also showed a statistically significant decrease from 70.3 ± 16.9 pg/mL at baseline to 20.9 ± 8.0 pg/mL at 12 weeks (P < 0.001, Wilcoxon signed-rank test). A statistically significant positive correlation (Spearman’s ρ = 0.672, P < 0.001) was observed between reduction in PASI score and in serum survivin levels at the end of the 12-week study period [Figure 2]. The decrease in PASI scores every 4 weeks and the corresponding decreased survivin levels at baseline and 12 weeks Scatter diagram depicting a co-relation of PASI scores with serum survivin levels over a period of 12 weeks (r = 0.672) . "Survivin_diff" and "PASI_diff" means the difference in survivin levels and difference in PASI scores, respectively, following treatment Discussion The overall clinico-demographic profile of the studied patients corroborates with studies which have described patients with psoriasis/psoriatic disease commonly presenting in early to middle adulthood, showing a balanced sex distribution.[1314] Survivin, an important member of the IAP family, has recently gained attention in the pathogenesis of psoriasis due to its dual role in promoting keratinocyte proliferation and inhibiting programmed cell death.[15] Although hormonal influences have been suggested for sex-specific variability in some studies, gender-independent expression patterns have been observed in psoriatic individuals.[1617] Given its pathophysiological significance in hyperproliferative and immune-mediated disorders, this study investigated and compared serum survivin levels in patients with chronic plaque psoriasis and healthy controls. The objective of the study was to investigate a potential correlation between the severity of psoriasis and serum survivin levels. This would help us understand whether survivin could be a reliable biomarker that reflects clinical disease severity correlating with treatment with methotrexate. Increased survivin expression has been associated with disease severity and defective apoptotic regulation in other autoimmune and inflammatory disorders.[1518] Serum survivin levels in this study were significantly elevated in psoriasis patients compared to healthy controls (P < 0.001), highlighting contribution of heightened survivin expression to the pathological proliferation and apoptosis resistance observed in keratinocytes. This reinforces its etiological relevance and its potential as a biomarker of disease activity. Existing literature also suggests that survivin levels correspond with immune activation and inflammatory status in psoriasis.[19] We observed a significant decrease in mean serum survivin levels from 70.3 ± 16.9 pg/mL to 20.9 ± 8.0 pg/mL (P < 0.001) after 12 weeks of methotrexate therapy. It suggests that methotrexate also exerts its anti-inflammatory and anti-proliferative effects perhaps through downregulation of survivin-related molecular pathways for its therapeutic efficacy in reducing disease severity reflected by marked reduction in PASI score. Comparable findings have been documented in previous studies which associated decreased survivin expression with clinical improvement in psoriasis.[20] This is also noted in this study. Treatment with methotrexate led to a significant reduction in baseline PASI score from 15.3 ± 4.8 to 7.5 ± 4.4 at week 12 (P < 0.001) and a consequent decreased disease severity. A positive correlation was also observed between reductions in survivin levels and improvement in PASI scores (r = 0.672, P < 0.001), supporting the utility of survivin as a responsive biomarker of therapeutic outcome. Overall, these findings support the therapeutic value of methotrexate in not only mitigating the clinical manifestations of psoriasis but also downregulating associated inflammatory markers. Although several biologic agents have demonstrated superior response rates for achieving PASI 75 and PASI 90, we used methotrexate in this study, as it still remains a widely used, economically affordable therapeutic option in clinical practice, especially in resource-limited settings.[21] Studies have also demonstrated comparative efficacy of methotrexate versus biologics.[222324] Given survivin’s integral role in regulating keratinocyte survival and inflammatory processes, their downregulation is likely a key contributor to the observed clinical benefits of methotrexate therapy. Thus, decreased serum levels of survivin after treatment can be a useful marker of therapeutic efficacy of methotrexate or possibly of other modalities as well. Yet, we also do not completely rule out the possibility that this reduction may not be attributable specifically to methotrexate alone. Psoriasis severity can change on its own, even without treatment. The disease often follows a relapsing–remitting course where symptoms may flare up and then improve spontaneously. Lifestyle factors such as smoking and alcohol also play a role in increasing survivin levels, which can be reduced by avoiding these habits. Anti TNFα therapy (e.g. infliximab) has also been shown to decrease survivin expression in psoriatic lesions. Interleukin-17 receptor A inhibitor therapy (e.g., brodalumab) led to a significant reduction in both serum and tissue survivin after 12 months, alongside clinical improvement (lower PASI and dermatology life quality index scores). Overall, many patients benefit from consistent treatment to reduce flares and maintain control. Monitoring severity with tools like the PASI score helps track these natural changes alongside treatment effects. Thus, methotrexate treatment would definitely be a contributing factor for reduced PASI scores and survivin levels, but the other factors cannot be completely ruled out.[252627] Limitations of the study The study is limited by the small sample size which limits generalizability and statistical power. The short duration of 12 weeks may not capture long-term effects of methotrexate on fluctuations in survivin levels and understanding of its role in disease progression. Evaluation of histopathological correlation and tissue survivin levels was not part of the study. Lack of long-term follow-up was another limitation. There remains a possibility of noncompliance by study subjects for abstaining from smoking/alcohol consumption. Conclusion This study demonstrates that serum survivin levels are significantly elevated in patients with moderate to severe psoriasis compared to healthy controls, and they correlate positively with disease severity/PASI score. Treatment with methotrexate for 12 weeks effectively reduced serum survivin levels, correlating with reduction in PASI score, underscoring its anti-inflammatory and antiproliferative effects. The findings support survivin as a potential biomarker for disease activity and therapeutic response to methotrexate, a cost-effective therapeutic option in psoriasis management. Investigating the molecular mechanisms linking survivin with inflammatory and metabolic pathways may offer novel therapeutic targets. However, these observations must be interpreted with caution, considering the aforementioned limitations. Well-designed experimental and prospective clinical studies with other therapies including biologics are highly desired to validate our observations and clarify survivin modulation across different treatment modalities. Authors’ contribution The manuscript has been read and approved by all authors. All authors meet authorship criteria and that the manuscript represents honest work. Data availability statement The data that support the findings of this study are available from the corresponding author, upon reasonable request. Conflicts of interest There are no conflicts of interest. Use of artificial intelligence (AI) The preparation of this manuscript was carried out entirely by the authors without the use of artificial intelligence technologies.